12 articles found
Browse Rainier Rehab's editorial coverage of Medication-assisted-treatment. Our writers track federal and state policy, peer-reviewed research, treatment innovations, and frontline reporting from the addiction recovery field. Each article in this collection cites primary sources — government datasets (SAMHSA, NIH, CDC), Medicaid and Medicare bulletins, JAMA and Lancet studies, and on-the-record statements from clinicians, regulators, and people in recovery — so readers can verify claims and dig deeper.
We update this tag whenever new medication-assisted-treatment reporting publishes. If you're a researcher, journalist, or family member trying to make sense of substance use disorder treatment, this is the working archive. For a directory of accredited treatment facilities, visit our facilities directory; to compare modalities, see our treatments overview and levels of care guide.
UC San Diego researchers identify liver-based genetic markers for cocaine addiction, opening new avenues for medication development beyond brain-targeting approaches.
Federal scientists approve phase I study of mitragynine, opening new frontiers in opioid addiction research amid ongoing debates over kratom's safety and efficacy.
In a major policy shift, the FDA now advises that buprenorphine and methadone should not be withheld from patients taking benzodiazepines or other CNS depressants.
Missouri hospital launches innovative pilot program providing medication and guaranteed virtual addiction appointments within 72 hours to rural patients with opioid use disorder.
New research reveals how cAMP signaling in brain neurons drives GLP-1 weight loss effects, opening pathways to enhance addiction treatments.
University of Reading study finds single psilocybin dose reduces neuropathic pain for weeks and makes standard painkillers work better.
New real-world evidence shows extended-release buprenorphine significantly outperforms other medication-assisted treatments in preventing relapse and reducing healthcare costs.
University of Cincinnati study demonstrates that embedding addiction treatment into primary care residency training expands patient access and boosts physician confidence in treating SUDs.
New NIH-funded research shows oral GLP-1 drugs like orforglipron reach the central amygdala, opening potential pathways for treating substance use disorders.
Forty-two addiction specialists establish consensus best practices for initiating medications for opioid use disorder in hospitals, adapting protocols for the fentanyl era.
NIH-funded trial shows GLP-1 drug combined with cognitive behavioral therapy significantly reduces heavy drinking days in patients with alcohol use disorder and obesity.
University of Kentucky researchers find that experimental Alzheimer's medication MW150 could reduce brain inflammation and neural damage during alcohol withdrawal, potentially lowering relapse rates.